reMYND Commences P-l Study of RES19-T for Alzheimer’s Disease

 reMYND Commences P-l Study of RES19-T for Alzheimer’s Disease

reMYND Commences P-l Study of RES19-T for Alzheimer’s Disease

Shots:

  • The P-l trial will evaluate the safety, tolerability, and PK of ReS19-T for the treatment of AD. In preclinical studies, ReS19-T has shown to robustly restore synaptic plasticity with an acute response and improve inflammation and AD pathology over a longer treatment duration
  • reMYND has a broad pipeline of novel programs in development, with a diabetes program scheduled to initiate human trials in mid-2021
  • RES19-T is a novel approach addressing the AD at its root and restore cognition in patients by reducing the cellular damage associated with memory loss

Click here ­to­ read full press release/ article | Ref: Globe Newswire | Image: reMYND

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post